We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Clinical Trial of Deferasirox Combination Treatment With Deferiprone In Thalassaemia Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02198508
Recruitment Status : Completed
First Posted : July 23, 2014
Last Update Posted : July 23, 2014
Information provided by (Responsible Party):
Ching-Tien Peng, China Medical University, Taiwan

Brief Summary:

Background: Three iron chelators now available on the market differ in toxicity and organ specificity; evidence on standardized chelation protocol remains inconclusive, but patients with transfusion-dependent beta-thalassemia treated with DFO infusion show significant differences in the limitations of daily activities, physical activity, and quality of life when treated with oral chelator. With licensing of DFP in America, it is reasonable to combine DFP with DFX. Patients find two oral chelators more acceptable than one oral and one injectable. This pilot study rates use of DFP for improving iron excretion profile of deferasirox.

Methods: The investigators enrolled 13 beta-thalassemia patients in China Medical University Children's Hospital in May 2009-October 2011. Five refused to take part in pharmacokinetics; they only participated in iron excretion study. Seven with irregular bowel function were unable to collect feces in the screening period as baseline data. Subjects were randomly assigned and rotated to undergo all treatments (with informed consent): (A) single oral dose of DFX 30 mg/kg once daily, (B) single oral dose of DFP 40 mg/kg twice a day, (C) oral doses of DFX and DFP administered sequentially (DFX 30 mg/kg/d, deferiprone 40 mg/kg/d and deferiprone 40 mg/kg/d at 7-hour intervals). Three-day drug dosage was followed by four-day washout. Collections of urine and stool proceeded 24 hours per day, each analyzed separately. Through a venous catheter, serial blood samples (1 mL/each sampling) were collected in glass tubes containing heparin as anticoagulant at Time 0 (pre-dosing) and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 6, 7, 8, 10, 12 and 24 hours after dose; plasma concentrations of DFP and DFX were measured.

Condition or disease Intervention/treatment Phase
Beta-thalassemia Major Drug: DFX(Deferasirox) Drug: DFP(Deferiprone) Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 13 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Shuttle Effect : Combination Therapy With Deferiprone and Deferasirox in Transfusion-dependent Thalassemia Patients.
Study Start Date : July 2007
Actual Primary Completion Date : July 2008

Arm Intervention/treatment
Active Comparator: DFX single treatment
a single oral dose of DFX 30 mg/kg once daily, (Exjade®, Novartis Pharmaceuticals Corporation, USA )
Drug: DFX(Deferasirox)
Other Name: Exjade®, Novartis Pharmaceuticals Corporation, USA

Active Comparator: DFP single treatment
single oral dose of DFP 40 mg/kg/day twice a day, (Kelfer®, Cipla Ltd., India)
Drug: DFP(Deferiprone)
Other Name: Kelfer®, Cipla Ltd., India

Experimental: combination treatment
sequential oral doses of DFX 30 mg/kg/d, DFP 40 mg/kg/d and DFP 40 mg/kg/d (dosing interval: seven hours).
Drug: DFX(Deferasirox)
Other Name: Exjade®, Novartis Pharmaceuticals Corporation, USA

Drug: DFP(Deferiprone)
Other Name: Kelfer®, Cipla Ltd., India

Primary Outcome Measures :
  1. iron excretion from urine and feces by flame atomic absorption spectroscopy [ Time Frame: 25-days ]
    Collections of urine and stool (made 24 hours a day) were analyzed separately.

Secondary Outcome Measures :
  1. drug concentration in plasma by pharmacokinetics analysis [ Time Frame: 25-day ]
    Through a venous catheter, serial blood samples (1 mL/each sampling) were collected into glass tubes containing heparin as an anticoagulant at time 0 (pre-dosing) and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 6, 7, 8, 10, 12 and 24 hours after dosing. Blood samples were centrifuged, with plasma collected and frozen at -20°C until analysis.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 18 years of age or older
  • serum ferritin greater than 2000 ng/mL,
  • serum creatinine within normal range for a measuring laboratory
  • platelet count exceeding 140000/mm3
  • body weight at least 40 Kg
  • None had a history of clinical significant of gastrointestinal, hepatic, renal, endocrine, oncologic, infectious, pulmonary or cardiovascular disease

Exclusion Criteria:

  • HIV positive, history of immunologic hypersensitivity to any medication
  • women pregnant or breast feeding
  • drug or alcohol abuse
  • patients showed abnormal or irregular bowel function (defined as more than three bowel movements a day or less than one bowel movement every other day)
  • receiving warfarin, digoxin, or anti-arrhythmic or antiseizure medication.
Layout table for additonal information
Responsible Party: Ching-Tien Peng, superintendent, China Medical University, Taiwan
ClinicalTrials.gov Identifier: NCT02198508    
Other Study ID Numbers: DMR-096-IRB-037
First Posted: July 23, 2014    Key Record Dates
Last Update Posted: July 23, 2014
Last Verified: July 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Hematologic Diseases
Genetic Diseases, Inborn
Iron Chelating Agents
Chelating Agents
Sequestering Agents
Molecular Mechanisms of Pharmacological Action